BRD2 and neoplasm: Despite the current possibilities of NAT, some patients have residual involvement in the breast or axillary lymph nodes after NAT due to several factors (e.g., different sensitivity to NAT in specific BC subtypes, treatment resistance, tumor biology, treatment toxicity, etc.).